Zydus Lifesciences Launches Anyra, India’s First Indigenous Biosimilar of Aflibercept 

Key Highlights: 

• Zydus Lifesciences has launched Anyra, India’s first indigenously developed biosimilar of Aflibercept (2 mg), following an agreement with Regeneron Pharmaceuticals and Bayer to support its commercialization in the country. 
• The therapy is indicated for multiple retinal diseases including Age-related Macular Degeneration (wet AMD), Diabetic Macular Edema, Diabetic Retinopathy, retinal vein occlusion, and myopic choroidal neovascularization—conditions affecting millions of patients in India who require anti-VEGF treatments to prevent vision loss. 
• With over 100 million people living with diabetes in India and millions at risk of retinal complications, the launch of Anyra aims to improve affordability and long-term access to biologic therapies. The product also strengthens Zydus’s biologics portfolio, which includes more than 13 biosimilars developed and manufactured in India. 

Implications:  

Anyra smashes Eylea pricing barriers, flooding retina clinics with budget-friendly therapy that keeps patients compliant for years. 
Zydus seizes ophthalmology dominance as diabetic eye complications explode, sidelining imports while combo regimens take off. 
Biosimilar breakthrough accelerates retinal care revolution, handing diabetologists powerful tools to preserve vision nationwide. 

Source: Expresspharma | Image: Zydus